We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Are the Projected Market Size and Growth Rates for the Blood Based Biomarkers Market From 2025 To 2029?

There has been a swift expansion in the market size of blood-based biomarkers in the past few years. It is projected to rise from $23.13 billion in 2024 to $26.06 billion in 2025, showcasing a compound annual growth rate (CAGR) of 12.6%. The proliferation during the historic phase can be traced back to a global increase in cancer cases, wider acceptance of personalized medicine, amplified investments in biomarker research, the broadening of clinical trials that involve biomarkers, and an upsurge in approvals for companion diagnostics.

The market size for blood based biomarkers is predicted to experience a swift expansion in the coming years, with an anticipated value of $41.55 billion in 2029 and a CAGR of 12.4%. This anticipated growth within the forecast period can be credited to the introduction of AI and machine learning in biomarker analysis, a growing need for early detection of diseases, expansion of telemedicine and remote diagnosis, an increased incidence of chronic illnesses, and improved health consciousness among consumers. Key trends for the forecast period incorporate AI-facilitated biomarker discovery, advancements in liquid biopsy, the integration of multi-omics, point-of-care (POC) testing devices, and breakthroughs in next-generation sequencing (NGS).

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp

What External and Internal Drivers Are Contributing to the Growth of the Blood Based Biomarkers Market?

The increasing incidents of cardiovascular diseases are projected to spur the expansion of the blood-based biomarkers market. These diseases include a variety of disorders that affect the heart and blood vessels, encompassing conditions such as coronary artery disease, heart failure, and stroke. The escalation in these diseases is primarily due to rising risk factors, including poor dietary habits and increased instances of obesity. Blood-based biomarkers are instrumental in diagnosing and monitoring cardiovascular diseases by offering valuable data on disease progression, risk evaluation, and treatment response via detectable substances in the blood. For example, in September 2024, the National Center for Biotechnology Information, a United States government agency, reported on a worldwide health research initiative. Predictions showed a 90% increase in the prevalence of cardiovascular diseases between 2025 and 2050, with predicted cardiovascular deaths reaching 35.6 million by 2050. Consequently, the surge in cardiovascular diseases is fueling the growth of the blood-based biomarkers market.

What Segment Types Define the Blood Based Biomarkers Market Structure?

The blood based biomarkers market covered in this report is segmented –

1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers

2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies

3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications

4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users

Subsegments:

1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions

2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins

3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels

4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells

5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity

Request customized data on this market:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Blood Based Biomarkers Market?

North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Blood Based Biomarkers Market?

Key players in the market for blood-based biomarkers are investing in technological enhancements, including highly accurate blood biomarker tests, to assist doctors in diagnosing Alzheimer’s disease. A high-precision blood biomarker test is a diagnostic instrument which uses specific biomarkers found in the blood to identify diseases or monitor health conditions accurately and reliably. For example, Quanterix, a life sciences company based in the US, introduced a high-precision blood biomarker test called LucentAD p-Tau 217 in October 2023. This tool aids in diagnosing Alzheimer’s disease in cognitively impaired adults by measuring the phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker that is closely associated with Alzheimer’s disease pathology, especially the accumulation of amyloid in the brain. Boasting over 90% accuracy, the LucentAD p-Tau 217 test meets stringent diagnostic standards. It is however meant to complement other diagnostic tools rather than serve as a standalone test.

View the full report here:

https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report

What Is the Definition of the Blood Based Biomarkers Market?

Blood-based biomarkers are measurable substances in the blood that indicate the presence or progression of a disease, as well as an individual’s response to treatment. Their primary purpose is to enable early disease detection, guide personalized treatment decisions, and monitor treatment efficacy with minimal invasiveness.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/customise?id=24176&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model